Vertex announced a global exclusive collaboration with Halozyme Hypercon, Inc., granting Vertex a license to use Halozyme’s Hypercon™ microparticle technology for up to three drug targets. The agreement includes a $15 million upfront payment, with additional milestone payments and royalties on net sales to be paid in the future.
Hypercon™ enables the hyperconcentration of drugs and biologics, allowing the same therapeutic dose to be delivered in a smaller injection volume. This capability supports at‑home administration and could improve patient adherence. Vertex plans to apply the technology across its pipeline, which includes cystic fibrosis, sickle cell disease, IgA nephropathy, and other serious diseases.
The deal expands Vertex’s technology portfolio and complements its existing drug‑delivery capabilities. Halozyme’s Hypercon platform is a natural extension of its ENHANZE® technology, and the company has already licensed Hypercon to major pharmaceutical partners such as Janssen, Eli Lilly, and argenx.
Halozyme acquired the Hypercon technology from Elektrofi in Fall 2025 for a $750 million upfront payment plus up to $150 million in milestone payments. The licensing agreement with Vertex is a material event that could accelerate the development and commercialization of Vertex’s next‑generation biologics and small‑molecule therapies.
Mark Bunnage, Executive Vice President and Chief Scientific Officer of Vertex, said the collaboration “adds a versatile delivery platform to Vertex’s toolbox as we pursue transformative therapies for patients with serious diseases.” Helen Torley, President and CEO of Halozyme, noted that the partnership “highlights the versatility of Hypercon and its potential to improve patient access to targeted biologics.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.